Saints' win over Cowboys ends with final score that's never been seen before in NFL history ‘Longlegs,’ ‘Three Women’ actor ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.

Instead of four equal quarterly distributions, AstraZeneca insists on two payments per year, with a greater portion announced ...

If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its share ...

AbbVie(NYSE:ABBV) is navigating a period of significant developments, including a robust 4% increase in operational sales and ...

In the ad for oral CGRP inhibitor Ubrelvy (ubrogepant), Williams is depicted as suffering from a migraine while in a talk ...

The stock's fall snapped a two-day winning streak.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In comparison, at its current levels of around $195, AbbVie stock trades at 18x expected 2024 earnings of $10.88 per share. This compares with the 12x average P/E multiple for ABBV seen over the last ...

But the risk of a serious side effect appears to be higher than previously known. By Anna Kodé AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and ...

AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...